These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 16963144)

  • 21. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
    Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
    Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
    Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
    J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel local drug delivery system using thermoreversible gel in combination with polymeric microspheres or liposomes.
    Arai T; Benny O; Joki T; Menon LG; Machluf M; Abe T; Carroll RS; Black PM
    Anticancer Res; 2010 Apr; 30(4):1057-64. PubMed ID: 20530409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
    Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [PEG-liposome in DDS and clinical studies].
    Maruyama K
    Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
    Cheng WW; Allen TM
    J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals.
    Qin Y; Chen H; Zhang Q; Wang X; Yuan W; Kuai R; Tang J; Zhang L; Zhang Z; Zhang Q; Liu J; He Q
    Int J Pharm; 2011 Nov; 420(2):304-12. PubMed ID: 21945185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Basic studies on chemotherapy of brain tumors by means of liposomes: affinity of sulfatide-inserted liposomes to human glioma cells].
    Kito A; Yoshida J; Kageyama N; Inoue I; Abe H; Arichi S; Kojima N; Yagi K
    No To Shinkei; 1987 Aug; 39(8):783-8. PubMed ID: 3426863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy.
    Li L; ten Hagen TL; Hossann M; Süss R; van Rhoon GC; Eggermont AM; Haemmerich D; Koning GA
    J Control Release; 2013 Jun; 168(2):142-50. PubMed ID: 23524188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted delivery via avidin fusion protein: intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes.
    Soininen SK; Lehtolainen-Dalkilic P; Karppinen T; Puustinen T; Dragneva G; Kaikkonen MU; Jauhiainen M; Allart B; Selwood DL; Wirth T; Lesch HP; Määttä AM; Mönkkönen J; Ylä-Herttuala S; Ruponen M
    Eur J Pharm Sci; 2012 Dec; 47(5):848-56. PubMed ID: 22985874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.
    Ying X; Wen H; Lu WL; Du J; Guo J; Tian W; Men Y; Zhang Y; Li RJ; Yang TY; Shang DW; Lou JN; Zhang LR; Zhang Q
    J Control Release; 2010 Jan; 141(2):183-92. PubMed ID: 19799948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
    Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
    J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
    He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
    Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
    Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R
    J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disaccharide-modified liposomes and their in vitro intracellular uptake.
    Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
    Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia.
    Gaber MH
    J Biochem Mol Biol Biophys; 2002 Oct; 6(5):309-14. PubMed ID: 12385965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of adriamycin entrapped by sulfatide-containing liposomes on ovarian tumor-bearing nude mice.
    Kojima N; Ueno N; Takano M; Yabushita H; Noguchi M; Ishihara M; Yagi K
    Biotechnol Appl Biochem; 1986 Oct; 8(5):471-8. PubMed ID: 3768148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
    J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.